Open AccessMetformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects
Author(s) -
Federico Argüelles-Tello,
Ashuin Kammar-García,
Cristian Adolfo Trejo-Jasso,
Juan Carlos Huerta-Cruz,
Lina Marcela Barranco-Garduño,
Héctor Isaac Rocha-González,
Juan Gerardo Reyes-García
Publication year - 2022
Publication title -
international journal of clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.363
H-Index - 67
ISSN - 0946-1965
DOI - 10.5414/cp204180
Subject(s) - mazindol , metformin , medicine , glycemic , endocrinology , glycated hemoglobin , type 2 diabetes , prediabetes , diabetes mellitus , weight loss , obesity , insulin , dopamine
Obesity is the strongest risk factor for type 2 diabetes (T2D). We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D.